By Carlo Martuscelli 
 

GlaxoSmithKline PLC (GSK.LN) said that its majority-owned joint venture ViiV Healthcare has been granted marketing authorization by the European Commission for its HIV treatment Juluca.

Juluca has been approved for HIV-1 in adults who are virologically suppressed and who have been on an antiretroviral treatment regimen for at least six months, the GlaxoSmithKline said.

The treatment consists of two drugs in a single pill.

ViiV Healthcare Chief Executive Deborah Waterhouse said the decision will allow patients to access a complete treatment program that maintains low levels of the autoimmune virus with a single pill.

Pfizer Inc. (PFE) and Shionogi Limited are minority shareholders in ViiV Healthcare.

 

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

 

(END) Dow Jones Newswires

May 21, 2018 06:34 ET (10:34 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Gsk.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Gsk.